Puma Biotechnology (PBYI)
(Delayed Data from NSDQ)
$2.95 USD
+0.10 (3.51%)
Updated Nov 1, 2024 04:00 PM ET
After-Market: $2.94 -0.01 (-0.34%) 7:58 PM ET
4-Sell of 5 4
A Value C Growth B Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$2.95 USD
+0.10 (3.51%)
Updated Nov 1, 2024 04:00 PM ET
After-Market: $2.94 -0.01 (-0.34%) 7:58 PM ET
4-Sell of 5 4
A Value C Growth B Momentum A VGM
Zacks News
Novavax (NVAX) Q4 Earnings & Sales Miss Estimates, Stock Tanks
by Zacks Equity Research
Novavax's (NVAX) fourth-quarter earnings and revenues miss estimates. Stock tanks on moderate revenue guidance for 2024.
Jazz (JAZZ) Q3 Earnings Lag, Revenues in Line With Estimates
by Zacks Equity Research
Jazz's (JAZZ) fourth-quarter earnings miss estimates while sales meet the mark. Shares drop 1.5% post the announcement.
Iovance's (IOVA) Q4 Earnings & Sales Fall Short of Estimates
by Zacks Equity Research
Iovance (IOVA) reports dismal earnings in the fourth quarter. Management is in the process of commercially launching the recently approved melanoma drug Amtagvi in the United States.
Viatris' (VTRS) Q4 Earnings and Revenues Miss Estimates
by Zacks Equity Research
Viatris (VTRS) reports lower-than-expected fourth-quarter financial results, as both earnings and sales miss estimates. Stock declines in pre-market.
Acadia (ACAD) Q4 Earnings Lag, Sales Beat Estimates, Stock Down
by Zacks Equity Research
Acadia's (ACAD) fourth-quarter earnings miss estimates while revenues beat the same. Higher product sales drive year-over-year revenues. Shares fall in after-hours trading.
Apellis (APLS) Q4 Earnings Miss, Revenues Meet Estimates
by Zacks Equity Research
Apellis' (APLS) fourth-quarter 2023 bottom line misses estimates, while the top line meets the same. The newly approved product, Syfovre, drives year-over-year sales.
Denali's (DNLI) Q4 Earnings Miss, Pipeline in Focus, Stock Up
by Zacks Equity Research
Denali (DNLI) reports lower than expected fourth-quarter financial results. The stock, however, rises 38% on news of funding raised by the company, which is expected to strengthen its cash position.
Esperion (ESPR) Q4 Earnings Top, Stock Up on Strong Revenues
by Zacks Equity Research
Esperion's (ESPR) fourth-quarter earnings and sales beat estimates on the back of better-than-expected collaboration revenues.
Perrigo (PRGO) Q4 Earnings Top, Sales Lag Estimates, Misses View
by Zacks Equity Research
Perrigo (PRGO) reports mixed fourth-quarter 2023 results. Management issues fresh financial outlook for 2024, which were below our expectations. Stock price drops 10% after this announcement.
Rocket (RCKT) Registers Narrower-Than-Expected Loss in Q4
by Zacks Equity Research
Rocket Pharmaceuticals' (RCKT) fourth-quarter earnings beat estimates. Devoid of marketed drugs, the company did not report any revenues during the quarter.
Puma Biotechnology (PBYI) to Report Q4 Earnings: What's in Store?
by Zacks Equity Research
On Puma Biotechnology's (PBYI) fourth-quarter 2023 earnings call, investors' focus is likely to be on the sales performance of its sole marketed cancer drug, Nerlynx.
Theravance's (TBPH) Q4 Earnings & Revenues Surpass Estimates
by Zacks Equity Research
Theravance's (TBPH) fourth-quarter earnings and revenues beat estimates. The company achieves profitability on an adjusted basis during the same time. Stock rises.
Fate Therapeutics (FATE) Q4 Earnings Beat, Revenues Fall Y/Y
by Zacks Equity Research
Fate Therapeutics (FATE) reports encouraging fourth-quarter results as loss narrows year over year due to lower operating expenses.
Bausch (BHC) Q4 Earnings and Revenues Top Estimates
by Zacks Equity Research
Bausch (BHC) fourth-quarter earnings and sales beat their respective estimates. The guidance for 2024 looks encouraging.
BioMarin (BMRN) Posts Q4 Earnings Beat, Upbeat Voxzogo Sales
by Zacks Equity Research
BioMarin (BMRN) reports encouraging fourth-quarter results, with earnings and sales beating estimates. The rapid uptake of Voxzogo boosts revenues.
Intellia (NTLA) Beats on Q4 Earnings, Provides Pipeline Update
by Zacks Equity Research
Intellia's (NTLA) earnings beat estimates in the fourth quarter while the company reports negative revenues. Management provides developmental and regulatory updates on its key pipeline candidates.
Karuna's (KRTX) Q4 Loss Widens, Focus on Bristol Myers Buyout
by Zacks Equity Research
Karuna's (KRTX) fourth-quarter 2023 earnings and revenues miss estimates. The company is set to be acquired by Bristol Myers.
Intra-Cellular (ITCI) Q4 Loss Narrower Than Expected, Sales Miss
by Zacks Equity Research
Intra-Cellular (ITCI) reports mixed fourth-quarter 2023 results despite Caplyta sales rising year over year on the back of increasing prescription trends.
Moderna (MRNA) Beats on Q4 Earnings & Sales, Reiterates View
by Zacks Equity Research
Moderna (MRNA) beats expectations for earnings and sales. Management reiterates guidance to record around $4 billion from product sales in 2024.
United Therapeutics (UTHR) Q4 Earnings & Sales Beat Estimates
by Zacks Equity Research
United Therapeutics' (UTHR) fourth-quarter 2023 earnings and sales beat estimates. Tyvaso sales continue to drive the company's top line.
Repligen (RGEN) Stock Down on Q4 Earnings Miss, Revenues Fall Y/Y
by Zacks Equity Research
Repligen's (RGEN) fourth-quarter 2023 earnings miss estimates and decline year over year. Stock declines.
CRISPR (CRSP) Q4 Earnings Top on Collaboration Revenues, Stock Up
by Zacks Equity Research
CRISPR (CRSP) gains on encouraging fourth-quarter 2023 results, beating both earnings and revenue estimates on the back of collaboration revenues received from Vertex.
Puma Biotech (PBYI) Is Up 23.01% in One Week: What You Should Know
by Zacks Equity Research
Does Puma Biotech (PBYI) have what it takes to be a top stock pick for momentum investors? Let's find out.
AbbVie (ABBV) Announces Appointment of New CEO Robert Michael
by Zacks Equity Research
Robert Michael is set to succeed Richard A. Gonzalez as AbbVie's (ABBV) CEO, effective Jul 1, 2024.
Axsome (AXSM) Stock Falls Despite Q4 Earnings & Revenue Beat
by Zacks Equity Research
Axsome (AXSM) stock declines despite narrower-than-expected loss in the fourth quarter of 2023. Its sales also beat estimates.